The Tarascon Pharmacopoeia 2014 Professional Desk Reference Edition recently received 4 stars from Doody’s Review Service. According to reviewer, Lawrence P. Carey, BS, PharmD, from the Temple University School of Pharmacy, this reference “is more comprehensive than others of its kind, such as the various prescriber drug guides."
The Tarascon Pharmacopoeia® 2014 Deluxe Lab Coat Edition is an expanded version of the Classic Shirt-Pocket Edition, containing more drugs, black box warnings, evidence-based off-label indications for adults and pediatric patients, and additional tables. This reference also includes typical drug dosing (all FDA approved), available trade and generic formulations, metabolism, safety in pregnancy and lactation, relative drug pricing information, Canadian trade names, and an herbal & alternative therapies section. Multiple tables supplement the drug content, including opioid equivalency, emergency drug infusions, cardiac dysrhythmia protocols, pediatric drug dosing, and much more.
Tarascon is committed to providing health care providers the best available portable medical references. Our acclaimed series of pocket guides succinctly distills and organizes hard-to-remember yet vitally important clinical information. Written by experts in their fields, readers repeatedly tell us that they are "must-have" books.
Click here to view all Tarascon Pharmacopoeia products.
Used by prescribers around the world, including physicians, pharmacists, nurses, physician assistants, dentists, and medical transcriptionists, the Tarascon Pocket Pharmacopoeia® 2014 Classic Shirt-Pocket Edition continues its tradition as the leading portable drug reference packed with vital drug information to help clinicians make better decisions at the point of care.
Topics: mobile medicine, oncology, FDA, medication, primary care, Physician, CorTemp, doctors, General Medicine, HQ Inc, mobile medicine, pill, Prescribing, Proteus, Pyschiatry & Mental Health, Cardiology, Hospital Medicine Blog
Jones & Bartlett is pleased to announce the launch of the Jones & Bartlett Learning Author’s Corner, a resource for prospective and new authors. The site contains the most up-to-date, general information on art development, manuscript submission, the publishing process, and editorial contacts. It also houses pertinent documents including: author information forms, marketing questionnaires, and proposal guidelines.
Topics: allied health, education, health, Author, Contest, Jones & Bartlett, medicine, oncology, patient education, primary care, General Medicine, Authors, Prescribing, publication, Pyschiatry & Mental Health, Cardiology, Global Health Blog, Hospital Medicine Blog, Infectious Disease, text
Dr. Joseph Esherick Monthly Blog – August 2011
There has been considerable interest in antibiotic stewardship programs over the past decade given the increase in drug-resistant bacteria. The best way to combat the problem of drug-resistant bacteria is to develop systems which discourage the inappropriate initiation of antibiotics or the unnecessary prolongation of antibiotics. The measurement of serum procalcitonin levels can aid sound clinical judgment for decisions regarding proper antibiotic use.
Procalcitonin, the precursor peptide of calcitonin, is released in response to a body’s exposure to bacterial antigens or toxins. Furthermore, the procalcitonin levels are suppressed by exposure to cytokines activated during viral infections, namely interferon gamma. We know that the level of procalcitonin elevation is directly correlated with the severity of the bacterial infection. In addition, procalcitonin levels rise within 6-12 hours after symptom onset of bacterial infections and decrease by about 50% per day once a bacterial infection is under control.
A number of randomized controlled trials have led to the development of procalcitonin guided clinical algorithms for various infections which have been used throughout Europe. These protocols have led to a marked reduction in the use of antibiotics in adult patients treated in a variety of clinical settings with no increase in mortality or morbidity...
A new vaccine being developed by a team of researchers from the University of Copenhagen in Denmark may reduce the number of positive hepatitis C tests in the future. They are reporting one of the first successful trials in inoculating animals against the disease.
The hepatitis C virus (HCV) infects at least 170 million people worldwide and about 4 million people in the United States. It is a big public health problem because most acute hepatitis C infections become chronic which can lead to further liver problems like cirrhosis and cancer.
"The hepatitis C virus (HCV) has the same infection pathways as HIV," says Jan Pravsgaard Christensen, Associate Professor of Infection Immunology at the Faculty of Health Sciences, University of Copenhagen.
"Approximately one newly infected patient in five has an immune system capable of defeating an acute HCV infection in the first six months. But most cases do not present any symptoms at all and the virus becomes a chronic infection of the liver."